Carole Huntsman is the North America Head of Sanofi Genzyme and U.S. Country Lead. In this role, she is focused on driving the U.S. launches of Dupixent in Atopic Dermatitis, Asthma and Nasal Polyps, Sarclisa in Multiple Myeloma, and Cablivi in Acquired Thrombotic Thrombocytopenic Purpura (aTTP) as well as expanding Sanofi Genzyme’s leadership in Multiple Sclerosis, Immunology, Rare Disease, Rare Blood Disorders and Oncology. Carole is also responsible for the portfolio of Sanofi Genzyme products in Canada.
In her role as Country Lead, Carole leads the coordination of Sanofi’s presence in the U.S. spanning all Global Business Units and Functions. Sanofi’s Global Business Units include General Medicines, Sanofi Pasteur (Vaccines), Sanofi Genzyme (Specialty Care), and Consumer Healthcare.
Carole joined Sanofi Genzyme in 2012 as Vice President and Multiple Sclerosis Business Unit Head, North America, and led the successful launches of both Aubagio and Lemtrada. She also led the Global Multiple Sclerosis Franchise as Global Lead overseeing the strategic planning and direction for the MS Brands in markets globally. Most recently, Carole served as Head, Multiple Sclerosis, Oncology and Immunology North America with responsibility for the strategic direction and execution of the Sanofi Genzyme North America Portfolio including multiple launches.
Before joining Sanofi Genzyme, Carole was Senior Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono. In her over 30 years of pharmaceutical and biotech experience, she has also worked at Pfizer, Inc. and Muro Pharmaceuticals, an ASTA Medica company. Additionally, Carole was commissioned as an officer in the U.S. Army, spending four years on active duty and more than twelve years in the Army Reserves.
Carole earned her Master’s in Business Administration with a concentration in Marketing and Consulting from Boston College – Wallace E. Carroll Graduate School of Management and her Bachelor of Arts in History from Boston College.